It took a decade for her idea to be ready for primetime, but now it seems that her decision to drop out was undoubtedly a good call. Last year, Walgreen Co. announced that it would be installing Theranos Wellness Centers in pharmacies across the country, with locations already up and running in Phoenix and Palo Alto, California. And Holmes has raised $400 million in venture capital for Theranos, which is now valued at $9 billion (Holmes owns 50%).
The other two 30-year-olds on Forbes' List, Facebook founder Mark Zuckerberg and his former roommate and Facebook CEO Dustin Moskovitz, also have access to a wealth of information about people — but their data is less likely to directly save a life.
Read more: http://www.businessinsider.com/theranos-founder-elizabeth-holmes-is-a-billionaire-2014-9#ixzz3FEKgZ6iu
I think she might be single Nah
The next time you get a blood test, you might not have to go to the doctor and watch vials of blood fill up as the precious fluid is drawn from your arm.
No more wondering to yourself, "Ah, how much more can they take before I pass out?"
Instead you might be able to walk into a Walgreens pharmacy for a reportedly painless fingerprick that will draw just a tiny drop of blood, thanks to Elizabeth Holmes, 30, the youngest woman and third-youngest billionaire on Forbes' newly released annual ranking of the 400 richest Americans.
Revolutionizing the blood test is a golden idea.
Because of new testing methods developed by Holmes' startup Theranos, that lone drop can now yield a ton of information.
The company can run hundreds of tests on a drop of blood far more quickly than could be done with whole vials in the past — and it costs a lot less.
A Billion-Dollar Idea
Holmes dropped out of Stanford at 19 to found what would become Theranos after deciding that her tuition money could be better put to use by transforming healthcare
Released good data from trial today to expand usage of already approved drug and dumped 7 %.
"That said, we do have this from Needham and Co." "This morning Seattle Genetics reported positive top-line data from the pivotal AETHERA trial of ADCETRIS. The trial met its primary endpoint with a highly significant and meaningful increase in progression free survival (PFS). Investors, however, appear to be reacting negatively to the disclosure that a pre-planned interim overall survival (OS) analysis was not statistically significant, despite the fact that these data are not yet mature. We are buyers of SGEN shares on weakness
today as we believe concerns over the interim OS data are overblown." Less
May catch a good trade over the next couple days. I made good money on her but sold too soon at 25-28
Good to get a bit of help for the fires. Market could be better, not trading much but trying to hold some stocks.
Maybe better to put money in tin cans ehh. Go A's and Gigantes still a little hope.
Old and wet
Another genetic ipo with good partners but not very far along.
Rare disease biotech Xenon Pharmaceuticals files for a $52 million IPO
Xenon Pharmaceuticals, an early-stage biotech with a gene therapy discovery platform for rare diseases, filed on Wednesday with the SEC to raise up to $52 million in an initial public offering. Xenon has a number of collaboration and licensing agreements with large pharmaceuticals including Teva, Genentech and Merck for its preclinical research.
The company's discovery platform was used to develop uniQure's Glybera treatment for orphan disease lipoprotein lipase deficiency, the first gene therapy approved in the EU. February IPO uniQure (QURE) priced above its range but ended the first day down 14% and now trades down 36% below the IPO price. Xenon is eligible to receive mid single-digit royalties on net sales of Glybera. Teva is in Phase 2 trials for a gene therapy discovered by Xenon that is being developed to treat osteoarthritis. Genentech was cleared to begin a Phase 1 trial for Xenon's pain treatment and Merck is in preclinical development for cardiovascular disease. Xenon also has a variety of preclinical therapies for both orphan diseases (such as Dravet Syndrome) and large-market conditions (including acne).
Primary shareholders include Medpace (16%), Lipterx (11%), InterWest Partners (9%), Fidelity (7%), Invesco (5%) and CEO Simon Pimstone (4%).
The Burnaby, Canada-based company, which was founded in 1996 and booked $27 million in collaboration revenue for the 12 months ended June 30, 2014, plans to list on the NASDAQ under the symbol XENE. Xenon Pharmaceuticals initially filed confidentially on August 16, 2013. Jefferies and Wells Fargo Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
Sr. Hola, I have to assume this new tech will take time to mature. The amount of venture capital raised seems to add some validation.
As with anything you can be blindsided by some other new breakthrough like in batteries and Mr. Tesla wanting a huge battery factory and the technology changing so quickly.
Now we may soon have a good quantity of Hydrogen produced by genetically altered moss.
What a fun job being a venture capitalist.
Old and new ventures.
At Siluria Technologies, we're replacing crude oil with natural gas. Our catalytic process transforms methane—one of the most abundant, inexpensive and widely available hydrocarbons on earth—into transportation fuels and commodity chemicals in an efficient, cost-effective, scalable manner using processes that can be seamlessly integrated into existing industry infrastructure. With our technology, we can reduce oil imports, lower prices for consumers and businesses, increase profits for gas producers, reduce environmental emissions and bring about greater global stability.
They say they can make gas for a dollar from methane or natural gas etc. They have raised 96 million venture capital already, not public yet. Could have some pins in Natural gas etc. Any ideas on her I wish I had a few bucks in her but maybe other ways to play and just watch for now.
Spent the day yesterday on the SF. Bay in a 16 ft aluminum boat fishing with the oldest son. A little adventurous for an old guy, it gets rough in a hurry. Only caught a couple of small sharks and a striper and put them back.
Bio's doing well lately on merger magic I believe. How long before we retrace again in our uncertain world.
Best all Old
ISIS going along with KITE in my little basket, trying to retake 40. Nice while it lasts. May add to KITE later on the strength of the trials. Only phase 1 but great results for an early trial. Small sample but is leading KITE to expand trial for another indication and expect earlier approval maybe 2017.
Old and expanding.
Oliver (aka Mr. Fluffy) woke me at about 3:30 Sunday mourning with the doors shaking. The kids in San Jose felt quite a bit more. Very lucky that hour kept the injuries down
Old stirred not shaken.
Maybe a little too much wine with my last post.:) Natural I found Captpussy on a message board with a few people about like our little board here. They are at AGCYF. I haven't posted anything there but I like a couple of there calls.
Sr. Hola, Mister Natural, Welcome back to the world Mr. Natural. Seems a lot of trouble everywhere now that has creep in during the night and stains everything.
My family has been spread far and wide by the Irish diaspora many members in all parts of the world. The family surname is Foley and although very distant it has had an effect on all.
Perhaps time to consider other means to a just end if any can be found.
I'm still pinning my hopes on a bunch of genetic engineering stocks with promise and trying not to watch too much.
Babysittnig two Grandkids tonight, life is good
ARNI gamble for two shots on goal cancer drugs. Early but cheap. Found this from some bio guru and haven't really studied up on her much.
Old better do more dd.
Secondary priced at 9.50 and down 6 percent plus. I'm going to grab a bit when the smoke clears a bit more.
I have a little basket of almost all now. SGMO, KITE, BLUE,QURE, ISIS, and now CLDN. I believe Juno may do an ipo also. I'm sticking them away for awhile.
Old with a tear for Robin
Another genetics company starting trial in UK. I may get in as soon as secondary is priced.
I own a small piece of most of the genetic engineered co's. Now let's keep Janet quiet.
Old going slow